Roquefort Investments PLC (GB:ROQ) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Roquefort Therapeutics has announced promising results for its STAT-6 siRNA in treating immunological diseases, marking a significant advancement in its pre-clinical development. This innovative siRNA therapy, which targets a key factor in Type 2 inflammatory diseases, has shown efficacy in in vitro models and is part of a broader portfolio aimed at oncology and immunology fields. The company is actively seeking out-licensing deals with Big Pharma to further validate and capitalize on its siRNA programs.
For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.